Drug Manufacturers and Piramal Pharma's GHG Reduction Targets Approved by SBTi
Tuesday, 17 September 2024, 00:13
Drug Manufacturers Taking Action
Piramal Pharma has recently achieved a significant milestone by having its greenhouse gas (GHG) reduction targets approved by the Science Based Targets Initiative (SBTi). This approval is pivotal for drug manufacturers, signaling an increased responsibility towards environmental sustainability.
Details of the Approval
- The SBTi validated Piramal Pharma’s near-term targets aimed at reducing GHG emissions.
- This initiative showcases the commitment of drug manufacturers to combat climate change.
- Piramal Pharma's actions could inspire other pharmaceutical companies to adopt similar measures.
As a leader in the industry, Piramal Pharma's progress in sustainability reinforces the emerging trend within the pharmaceutical sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.